PRIMARY SCLEROSING CHOLANGITIS

This study tests whether a fecal microbiota transplant (FMT) can help people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). About 58 adults will receive either FMT or a placebo. The goal is to see if FMT can lower liver enzyme levels and improve s…

This study tests a drug called elafibranor in about 350 adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts in the liver. The goal is to see if the drug can slow disease progression and improve survival compared to a placebo. Participants wi…

This early study tests whether an oral treatment made from gut bacteria is safe and doable for people with primary sclerosing cholangitis (PSC), a rare liver disease. About 28 adults aged 18-76 will take the therapy and be monitored for side effects and completion of the full cou…

This study tests whether the drug BRS201 (a form of vitamin B12) can lower liver enzyme levels in people with primary sclerosing cholangitis (PSC), a chronic liver disease. About 28 adults with PSC will take the drug or a placebo for 4 weeks each, in random order, and have their …

This early-phase study tests whether the experimental drug TAK-781 is safe and tolerable. First, healthy volunteers receive either the drug or a placebo. Then, a small group of people with primary sclerosing cholangitis (PSC) receive the drug. The study also measures how the body…

This early study tests whether siplizumab can safely prevent the immune system from attacking a new liver in people with autoimmune hepatitis or primary sclerosing cholangitis. Eight participants will receive two doses of the drug around the time of transplant and be monitored fo…

This study creates a collection of blood, urine, stool, and other samples from up to 9,150 people with cholestatic liver diseases like primary biliary cholangitis and primary sclerosing cholangitis. Researchers will use these samples and health data to better understand how these…

This study collects bile and bile duct cells from people with Primary Sclerosing Cholangitis (PSC) and healthy volunteers. Researchers will grow these cells into mini-organs called organoids to better understand how PSC progresses and how bile duct cancer develops. The goal is to…

This study looks at gut bacteria in 3,000 adults with chronic liver diseases like autoimmune hepatitis and fatty liver. Researchers want to find specific bacteria patterns linked to each disease. The goal is to better understand how the gut and liver interact, which may lead to n…

This study looks at how statins, a common cholesterol medicine, change bile acids and gut bacteria in people with primary sclerosing cholangitis (PSC), a rare liver disease with no cure. Researchers will collect samples from 15 adults with PSC to understand the disease better. Th…

This study aims to understand what causes primary sclerosing cholangitis (PSC), a rare chronic liver disease. Researchers will collect blood, saliva, urine, stool, and tissue samples from 143 adults with PSC over 12 months. They will also perform imaging and surveys to gather dat…

This study follows 1,000 children with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. Researchers will collect medical data, DNA, and other samples to understand how PSC progresses and affects daily life. The goal is to identify factors that m…